Business Description
NeOnc Technologies Holdings Inc
NAICS : 541713
SIC : 2836
ISIN : US64051A1016
Total Employee Number:
5Description
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.4 | |||||
Equity-to-Asset | -3.97 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26 | |||||
3-Year EBITDA Growth Rate | -172.4 | |||||
3-Year EPS without NRI Growth Rate | -168.8 | |||||
3-Year FCF Growth Rate | -183.9 | |||||
3-Year Book Growth Rate | -112.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.96 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.01 | |||||
9-Day RSI | 40.8 | |||||
14-Day RSI | 42.7 | |||||
3-1 Month Momentum % | -23.03 | |||||
6-1 Month Momentum % | -48.42 | |||||
12-1 Month Momentum % | -13.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.13 | |||||
Quick Ratio | 0.13 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5 | |||||
Shareholder Yield % | -19.59 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -54265 | |||||
OCF Margin % | -54265 | |||||
ROA % | -891.68 | |||||
ROIC % | -906.66 | |||||
3-Year ROIIC % | -819.48 | |||||
ROC (Joel Greenblatt) % | -9584.05 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2205 | |||||
EV-to-EBIT | -3.23 | |||||
EV-to-Forward-EBIT | -6.8 | |||||
EV-to-EBITDA | -3.24 | |||||
EV-to-Revenue | 2864.18 | |||||
EV-to-FCF | -5.28 | |||||
Earnings Yield (Greenblatt) % | -30.96 | |||||
FCF Yield % | -18.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NTHI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeOnc Technologies Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.04 | ||
| EPS (TTM) ($) | -1.85 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 87.94 | ||
| 14-Day RSI | 42.7 | ||
| 14-Day ATR ($) | 0.446969 | ||
| 20-Day SMA ($) | 4.65425 | ||
| 12-1 Month Momentum % | -13.42 | ||
| 52-Week Range ($) | 3.69 - 12.99 | ||
| Shares Outstanding (Mil) | 25.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeOnc Technologies Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeOnc Technologies Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 133 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 59 days | ||
| General meeting for 2025 | 2026-08-14 10:00 | In 43 days | ||
| First quarter earnings results for 2026 | 2026-05-18 | 5.50 (-2.14%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 7.01 (+1.74%) | ||
| Annual report for 2025 | 2026-03-31 | 7.00 (-2.51%) | ||
| investor conference call | 2026-03-05 09:00 | 9.63 (+3.55%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 8.98 (-23.93%) | ||
| NeOnc Technologies (Nasdaq: NTHI) Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program | 2025-11-12 09:00 | 11.42 (+10.44%) |
Show
Entries
NeOnc Technologies Holdings Inc Frequently Asked Questions
What is NeOnc Technologies Holdings Inc(NTHI)'s stock price today?
The current price of NTHI is $4.41. The 52 week high of NTHI is $12.99 and 52 week low is $3.69.
When is next earnings date of NeOnc Technologies Holdings Inc(NTHI)?
The next earnings date of NeOnc Technologies Holdings Inc(NTHI) is 2026-08-31 Est..
Does NeOnc Technologies Holdings Inc(NTHI) pay dividends? If so, how much?
NeOnc Technologies Holdings Inc(NTHI) does not pay dividend.
Guru Commentaries on NAS:NTHI
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on NeOnc Technologies Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers